| Literature DB >> 21776367 |
Stella Marousi1, Anna Antonacopoulou, Haralambos Kalofonos, Panagiotis Papathanasopoulos, Marina Karakantza, John Ellul.
Abstract
Functional single-nucleotide polymorphisms (SNPs) of inflammatory cytokines have been previously related to the occurrence of an ischemic stroke (IS). We investigated whether five functional SNPs (i.e., TNF-α-308G>A, IL6-174G>C, IL12B 1188A>C, IL4-589C>T, and IL10-1082G>A) might be associated with the age of onset and 6-month outcome of an acute IS. A probe-free real-time PCR methodology was used to genotype 145 consecutively admitted cases with a first-ever IS. Simple Kaplan-Mayer and adjusted Cox regression analyses showed no association between inflammatory genotypes and the age of IS onset. IL6-174G>C, IL12B 1188A>C, IL4-589C>T, and IL10-1082G>A were not found to significantly contribute to the long-term outcome of the disease. However, carriage of the TNF-α-308 GG genotype was significantly associated with reduced odds for an adverse outcome. Larger studies are needed to confirm our results.Entities:
Year: 2011 PMID: 21776367 PMCID: PMC3138112 DOI: 10.4061/2011/792923
Source DB: PubMed Journal: Stroke Res Treat
Allele-specific primers and real-time PCR conditions.
| Allele-specific primers | Real-time PCR conditions | |
|---|---|---|
| IL4-589C>T | ||
| FRW C primer | 5′- | |
| REV primer | 5′-GGCAGAATAACAGGCAGAC-3′ | |
| IL10-1082G>A | ||
| FRW G primer | 5′- | |
| REV primer | 5′-CTGGATAGGAGGTCCCTTAC-3′ | |
| TNF- | ||
| FRW G primer* | 5′- | |
| FRW A primer* | 5′-AGGCTGAACCCCGT | |
| REV primer* | 5′-AAGGAAACAGACCACAGACCTG-3′ | |
| IL6-174G>C | ||
| FRW G primer* | 5′-A | |
| FRW C primer* | 5′- | |
| REV primer* | 5′-ATGACGACCTAAGCTGCAC-3′ | |
| IL12B 1188A>C | ||
| FRW A primer* | 5′-TTTCAATGAGCATTTAGCA | |
| FRW C primer* | 5′- | |
| REV primer* | 5′-TAGGATCACAATGATATCTTTGC-3′ |
*Primer designed on the complementary sequence. FRW: forward, REV: reverse.
Underlined are sites of introduced mismatches. Bold are the polymorphic alleles. Italic is the intoduced GC-tail.
Baseline characteristics and genotype frequencies of IS patients.
| Characteristic | IS patients |
|---|---|
| ( | |
| Age, median (IQR) | 68 (58–76) |
| Sex, females (%) | 50 (34.5) |
| Arterial hypertension (%) | 104 (72) |
| Diabetes mellitus (%) | 40 (28) |
| Hypercholesterolemia (%) | 102 (70) |
| Atrial fibrillation (%) | 31 (21) |
| Ischemic heart disease (%) | 37 (26) |
| Current smoking (%) | 52 (36) |
| Stroke severity on admission (%) | |
| Mild (SSS = 45–58) | 69 (48) |
| Moderate (SSS = 19–44) | 44 (30) |
| Severe (SSS = 0–18) | 32 (22) |
| TNF- | |
| GG (%) | 115 (79) |
| GA (%) | 30 (21) |
| IL6-174G>C | |
| GG (%) | 85 (59) |
| GC (%) | 50 (34) |
| CC (%) | 10 (7) |
| IL12B 1188A>C | |
| AA (%) | 77 (53) |
| AC (%) | 57 (39) |
| CC (%) | 11 (8) |
| IL4-589C>T | |
| CC (%) | 123 (84.8) |
| CT (%) | 22 (15.2) |
| IL10-1082G>A | |
| AA (%) | 47 (32.4) |
| GA (%) | 71 (49) |
| GG (%) | 27 (18.6) |
IQR: interquartile range, IS: ischemic stroke,
SSS: scandinavian stroke scale.
Figure 1Kaplan-Mayer curves for the disease-free survival analysis, according to the studied inflammatory genotypes.
Statistics of the disease-free survival analysis.
| Disease-free survival analysis | |||
|---|---|---|---|
| Median (SE) | KM log rank | Cox regression* | |
| Odds ratio (95% CI) | |||
| TNF- | |||
| GA | 65 (4.93) | .70 | Referent |
| GG | 68 (1.97) | 0.74 (0.49–1.12) | |
| IL6-174G>C | |||
| GG | 65 (2.01) | .86 | Referent |
| GC/CC | 69 (1.66) | 0.70 (0.51–1.22) | |
| IL12B 1188A>C | |||
| AA | 67 (2.00) | .62 | Referent |
| AC/CC | 70 (2.58) | 1.02 (0.72–1.44) | |
| IL4-589C>T | |||
| CC | 67 (2.08) | .91 | Referent |
| CT | 68 (4.10) | 1.07 (068–1.70) | |
| IL10-1082G>A | |||
| GA/AA | 68 (2.09) | .55 | Referent |
| GG | 65 (6.06) | 1.43 (0.92–2.22) | |
SE: standard error, KM: Kaplan-Mayer, CI: confidence intervals.
*Adjusted for sex, hypertension, diabetes, hyperlipidemia, atrial fibrillation, ischemic heart disease, and smoking.
Association of inflammatory genotypes with long-term functional outcome of an IS.
| Genotypes | Logistic regression | ||||
| TNF- | Presence of GG | ||||
|---|---|---|---|---|---|
| 6-month outcome | AG | GG | OR* | 95% CI | |
| (BI: 16–20) good (%) | 15 (17) | 73 (83) | Referent | 0.04–0.86 | .03 |
| IL6-174G>C | Presence of GC/CC | ||||
| GG | GC/CC | OR* | 95% CI | ||
| (BI: 16–20) good (%) | 54 (64.3) | 30 (35.7) | Referent | 0.37–3.54 | .82 |
| IL12B 1188A>C | Presence of AC | ||||
| AA/CC | AC | OR* | 95% CI | ||
| (BI: 16–20) good (%) | 48 (54.5) | 40 (45.5) | Referent | 0.23–2.09 | .52 |
| IL4-589C>T | Presence of CT | ||||
| CC | CT | OR* | 95% CI | ||
| (BI: 16–20) good (%) | 71 (84.1) | 14 (15.9) | Referent | 0.17–2.59 | .56 |
| IL10-1082G>A | Presence of GG | ||||
| GG | AG/AA | OR* | 95% CI | ||
| (BI: 16–20) good (%) | 14 (15.9) | 74 (84.1) | Referent | 0.57–12.40 | .22 |
BI: barthel index, OR: odds ratio, CI: confidence intervals.
*ORs adjusted for age, sex, hypertension, diabetes, hyperlipidemia, ischemic heart disease, smoking, stroke severity on admission and TOAST categories.